Novartis Says Mylan Infringed Lescol Patent
Novartis Pharmaceuticals Corp. on Tuesday accused Mylan Pharmaceuticals Inc. of infringing a patent covering the anti-cholesterol drug Lescol, less than two weeks after a court rejected Mylan's bid to make a...To view the full article, register now.
Already a subscriber? Click here to view full article